Oncology

Latest News

Video Series

Overcoming Barriers to TIL Use in Patients With Solid Tumors

TIL Therapy: Lessons Learned and Potential Future Directions in Care

Data from Additional Clinical Studies on Tumor-Infiltrating Lymphocyte Therapy

Results From the C-144-01 Trial and Potential Impact on Clinical Practice

Tumor-Infiltrating Lymphocyte Therapy: Clinical Data on Biologic Activity

Clinical Experience With TIL Therapy for Solid Tumors

Considerations for Use of TILs versus CAR T-cell Therapies

An Overview on Tumor-Infiltrating Lymphocyte Therapy for Solid Tumors

Latest Videos

Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.

Prerna Mewawalla, MD, on Unmet Needs Following Early-Line CAR T for R/R Multiple Myeloma

Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford

Surbhi Sidana, MD, on Cilta-Cel's Efficacy in Second-Line Relapsed/Refractory Multiple Myeloma

Alexey Danilov, MD, PhD, the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, codirector of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California

Alexey Danilov, MD, PhD, on CAR T and Bispecific Antibody Sequencing for DLBCL

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital

Matthew Ku, MBBS, PhD, FRACP, RACP, FRCPA/RCPA, on CAR T-Cell Therapy JNJ-90014496's Safety Profile in R/R LBCL

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine

Saurabh Dahiya, MD, FACP, on CAR-T KITE-363's Safety Profile in R/R B-Cell Lymphoma

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic

Shahzad Raza, MD, on Future Plans for CAR T-Cell Therapy NXC-201 in R/R Light Chain Amyloidosis

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Manali Kamdar, MD, on Lowering Barriers to Access for Liso-Cel Based on New Data

Shahzad Raza, MD, on Evaluating CAR-T NXC-201 in R/R Light Chain Amyloidosis

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology

Laura Aguilar, MD, PhD, on the Potential to Apply Immunotherapy DOC1021 to a Broad Array of Tumor Types

Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center

Jamie Jacobs, PhD, on Using a Digital App to Aid Caregivers for Patients Undergoing Hematopoietic Stem Cell Transplant

Shorts

0:48

From Pie in the Sky to Curing Leukemia

a month ago

1:03

Watershed Moments That Changed the Field

a month ago

0:26

Harnessing T-Cells for Immune-Based Cancer Treatments

2 months ago

0:47

The Role of CD4+ T-Cells in Cancer Therapy

2 months ago

1:02

Innovative Treatment Considerations for CAR-T Therapies

3 months ago

Stephen J. Schuster, MD, Abramson Cancer Center

0:47

The Importance of Nonmyeloablative Chemotherapy to Cell Therapy

3 months ago

Michael T. Lotze, MD

0:25

Which Therapy Predicts a Better Response to TIL in Melanoma?

3 months ago

Michael T. Lotze, MD

1:02

Unexpected Results in CAR T Cell Therapy Study in Glioblastoma

3 months ago

Marcela V. Maus, MD, PhD

1:30

The History and Evolution of CAR T Cell Therapy

3 months ago

Marcela V. Maus, MD, PhD

Podcasts

December 2, 2025

ImmunoLogic, Episode 7: "Turbocharging CAR T-Cells: The IL-9 Orthogonal Signal" With Anusha Kalbasi, MD

November 4, 2025

Quarter Century Update: The Impact of Artificial Intelligence

October 31, 2025

Quarter Century Update: Thoughts on Reducing Costs of Goods

October 30, 2025

Quarter Century Update: Future Predictions for the Field

October 29, 2025

Quarter Century Update: What Does the Field Need Most Right Now?

October 29, 2025

Quarter Century Update: What Lessons Should Guide the Next Generation of Developers and Regulators?

October 28, 2025

Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy

October 27, 2025

Quarter Century Update: How can Partnerships Between Academia, Biotech, and Pharma be Better Structured?

October 27, 2025

Quarter Century Update: Platform Approaches and Industry Investment

October 26, 2025

Quarter Century Update: Where are the Biggest Bottlenecks Today?

CME Content

In-Person + Virtual Event

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

December 5, 2025

Video

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

Craig Emmitt Cole, MD; Sikander Ailawadhi, MD; Irene Ghobrial, MD; Monique Hartley-Brown, MD, MMSc

Virtual Event

Medical Crossfire® Navigating the Chronic Myeloid Leukemia Landscape: Treatment Strategies, Mechanisms, and Patient-Centered Care

December 15, 2025

Virtual Event

Tackling Oncologic Emergencies in Patients Treated with High-Dose Methotrexate

December 17, 2025

Virtual Event

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies

December 18, 2025

Virtual Event

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

December 19, 2025

Multimedia

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

Elias Jabbour, MD

Video

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

Rami S. Komrokji, MD; Ghaith Abu-Zeinah, MD; Gabriela Hobbs, MD; Barbara Mora, MD

Video

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Cristina Gasparetto, MD; Katja Weisel, MD

Video

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Krina Patel, MD, MSc; Alfred L. Garfall, MD; Ajay K. Nooka, MD, MPH, FACP

Video

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Corey Cutler, MD, MPH, FRCPC; Amin M. Alousi, MD; Yi-Bin Chen, MD; Carrie Lynn Kitko, MD

Video

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Alexey V. Danilov, MD, PhD; Leidy L. Isenalumhe, MD, MS; Lori A. Leslie, MD; Mazyar Shadman, MD, MPH; Jason R. Westin, MD, MS, FACP

Video

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Elias Jabbour, MD; Hagop M. Kantarjian, MD; Aaron Logan, MD, PhD, MPhil; Rob Pieters, MD, PhD; Claire Roddie, MD, PhD

Video

Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next in B-Cell Malignancies

Catherine C. Coombs, MD, MS; Paolo Ghia, MD, PhD; Tycel J. Phillips, MD; Jeffrey V. Matous, MD; Grzegorz S. Nowakowski, MD, FASCO

Case-based Simulation

SimulatEd™ in Multiple Myeloma: Personalizing Care Plans to Treat Newly Diagnosed Patients

Amrita Krishnan, MD

In-Person Event

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

February 26-28, 2026

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

In-Person + Virtual Event

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

April 25-26, 2026

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Video

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

André H. Goy, MD; Jorge E. Cortes, MD; Sagar Lonial, MD, FACP

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

In-Person Event

10th Annual Live Medical Crossfire®: Hematologic Malignancies

July 11, 2026

Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Amrita Krishnan, MD; Meletios Athanasios (Thanos) C. Dimopoulos, MD; Shaji Kumar, MD; Katja Weisel, MD

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Case-based Simulation

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Jae Park, MD

Video

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

More News

Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center

Structuring Partnerships Among Academia, Biotech, and Pharma

ByRenier Brentjens, MD, PhD,Deborah Phippard, PhD,Noah Stansfield

November 27th 2025

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about streamlining collaboration to speed up advancement of new therapies.

Around the Helix: Cell and Gene Therapy Company Updates – November 26, 2025

ByNoah Stansfield

November 26th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind – November 21, 2025

ByNoah Stansfield

November 21st 2025

Review top news and interview highlights from the week ending November 21, 2025.

Platform Approaches and Industry Investment in Cell and Gene Therapy

ByRenier Brentjens, MD, PhD,Deborah Phippard, PhD,Noah Stansfield

November 20th 2025

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about strategies for streamlining development of novel therapies.

Around the Helix: Cell and Gene Therapy Company Updates – November 19, 2025

ByNoah Stansfield

November 19th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Bladder Cancer Gene Therapy Detalimogene Effects 62% CRR at 6 Months Posttreatment

ByNoah Stansfield

November 19th 2025

This finding came from an analysis of 37 patients treated in the phase 1/2 LEGEND trial.

Stephen M. Ansell, MD, PhD, the chair of the Division of Hematology, coleader of the Hematological Malignancies Program, and interim chair of the Department of Oncology at Mayo Clinic

Stephen M. Ansell, MD, PhD, on Integrating Cell Therapy into Clinical Practice in Oncology

ByStephen M. Ansell, MD, PhD,Noah Stansfield

November 18th 2025

The chair of the Division of Hematology at Mayo Clinic discussed practical considerations for the introduction of cell therapies for the treatment of hematologic malignancies.

CGTLive®’s Weekly Rewind – November 7, 2025

ByNoah Stansfield

November 7th 2025

Review top news and interview highlights from the week ending November 7, 2025.

What Were the Most Significant Inflection Points or Breakthroughs in Cell and Gene Therapy?

ByRenier Brentjens, MD, PhD,Deborah Phippard, PhD,Noah Stansfield

November 6th 2025

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed major events in the past quarter century of cell and gene therapy research.

Around the Helix: Cell and Gene Therapy Company Updates – November 5, 2025

ByNoah Stansfield

November 5th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Data Roundup: October 2025 Features Updates from ESMO, ESGCT, and More

ByNoah Stansfield

November 3rd 2025

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive® team.

CGTLive®’s Weekly Rewind – October 31, 2025

ByNoah Stansfield

October 31st 2025

Review top news and interview highlights from the week ending October 31, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – October 29, 2025

ByNoah Stansfield

October 29th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind – October 24, 2025

ByNoah Stansfield

October 24th 2025

Review top news and interview highlights from the week ending October 24, 2025.

Quarter Century Update: What Were the Most Significant Inflection Points or Breakthroughs in the Field?

ByDeborah Phippard, PhD,Renier Brentjens, MD, PhD,Noah Stansfield

October 23rd 2025

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed their thoughts on major moments in the past 25 years of cell and gene therapy research.